hGH
None
Technical catalog description
Human Growth Hormone (hGH) is a peptide hormone naturally produced by the anterior pituitary gland that regulates growth, cell reproduction, and cell regeneration.
Exogenous hGH administration provides numerous benefits including increased muscle mass, reduced body fat, improved recovery, enhanced skin quality, and potential anti-aging effects. Unlike anabolic steroids, hGH doesn’t directly bind androgen receptors but works through IGF-1 pathways and other growth-promoting mechanisms.
Read next
Mechanism details
hGH works primarily through two pathways: direct GH receptor binding (lipolysis, immune modulation, tissue repair) and stimulation of IGF-1 production in the liver. IGF-1 drives most of the anabolic effects attributed to GH, protein synthesis, satellite cell activation, and tissue growth. IGF-1 levels are the primary monitoring target on hGH protocols.
Unlike anabolic steroids, hGH does not activate androgen receptors and produces a fundamentally different quality of effect: reduced adipose tissue, improved connective tissue quality, accelerated injury recovery, improved skin and joint health, and slow but sustainable lean mass gain. The effects build over months, not weeks. Users who evaluate hGH progress on a 4-week timeline consistently underestimate it; the 6-month picture is dramatically different.
Timing: This catalog does not validate a morning, pre-sleep, or workout-based administration schedule for performance use.
Glucose risks: Somatropin labeling warns about impaired glucose tolerance and diabetes, and calls for glucose monitoring. This profile does not establish an IU/day amount at which those risks are manageable. See the Genotropin prescribing information for its product-specific warnings; they do not establish a regimen for performance use.
Water retention, hand numbness, joint stiffness, and reduced insulin sensitivity
Carpal tunnel-type symptoms when dose climbs too quickly
blood glucose
igf1 levels
IGF-1
fasting glucose / HbA1c
insulin sensitivity
edema and blood pressure
Active cancer workup or untreated diabetic control issues without medical supervision
Using high doses when blood glucose is already trending poorly
hGH is chosen for long-horizon body composition work: quality lean tissue gain over 4-6 months, simultaneous fat reduction, joint and connective tissue recovery support, and the broader wellness and recovery improvement it provides. It is rarely the primary anabolic driver of a cycle; it supports and amplifies what anabolic steroids do.
Users with joint or injury issues often find hGH meaningfully improves recovery and structural health in a way steroids do not.
Unverified community-use description: Users report changes in sleep, skin, joint comfort, and fluid retention. These accounts do not establish a dose at which adverse effects resolve or a predictable onset timeline.
Month 3-4: Body composition changes become visible. Lean mass gain is real but modest. The cumulative fat loss effect becomes significant.
Some community reports describe effects over months. These reports are unverified and do not establish a treatment length or an effective amount.
Increasing an amount because early effects seem subtle. This catalog does not validate IU/day thresholds for effectiveness or tolerability.
Expecting steroid-like feedback speed. The mechanism is different and the timeline is different. Users who run hGH for 6 weeks and conclude it “doesn’t work” missed the entire benefit window.
Using a product-quality concern to choose an amount or schedule. This profile does not provide a testing timetable that validates a performance-use regimen.
Compared with peptide GH secretagogues (Ipamorelin, CJC-1295), direct GH is more predictable in dose-to-effect relationship and does not rely on pituitary GH reserve. Secretagogues work by stimulating the pituitary to release GH, which requires a functioning pituitary and sufficient reserve, and produces pulsatile GH release rather than stable exogenous levels. Direct GH is often preferred for users who want precise, consistent GH activity.
Compared with IGF-1 LR3, direct GH produces IGF-1 systemically via liver conversion, while IGF-1 LR3 injected locally or systemically bypasses the GH-IGF-1 axis entirely. The mechanisms are different and they can be combined, but they are not interchangeable.